Sign in
Taking people in South AfricaNo phase

Tests a smoking quit program for people with HIV or TB in South Africa

Tests a combined smoking quit program in adults with HIV or tuberculosis.

Key facts

Who runs it
Massachusetts General Hospital
Where
Rondebosch, South AfricaSee the site
Trial code
Registry title
South Africa Smoking Cessation and Engagement in HIV/TB Care Care
Status
Recruiting
People taking part
83 people, planned
Started
12 Mar 2024
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • QUIT-AD
  • Enhanced Treatment as Usual
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in Cape Town who smoke and live with both HIV and TB, and want to quit smoking.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Living with HIV and within 4 months of starting or restarting TB treatment, with a positive GeneXpert test or sputum culture.
Earlier treatment
Must have taken ART for at least three months. Cannot be using other medicine for quitting smoking, or have started cognitive behavioral therapy for smoking in the past year.
Biomarker or test result
HIV confirmed in the medical record; TB confirmed by a positive GeneXpert test or sputum culture.

Main reasons for not taking part

  • Untreated or unstable mental health condition that gets in the way, such as psychosis or bipolar disorder
  • Currently using other medicine to quit smoking
  • Cognitive behavioral therapy for smoking started in the past year
  • TB outside the lungs or drug-resistant TB (MDR or XDR)

This trial only enrols participants living with HIV. The registry sentence this rests on: Living with HIV, confirmed via medical record, and history of taking ART for at least three months (consecutively or non-consecutively)

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Aged 18 or older
  • Willing and able to provide written informed consent
  • Living with HIV, confirmed via medical record, and history of taking ART for at least three months (consecutively or non-consecutively)
  • Within 4 months of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture
  • Habitual smoker operationalized as smoking at least 4 days a week
  • Motivation (> 5/10) to quit smoking or > 24 hour quit past yr
  • Must be living in the catchment area for either the Town Two Clinic or the Michael Mapongwana Community Health Clinic in Khayelitsha

Who cannot take part

  • Cognitive Behavioral Therapy for smoking cessation initiated within the past year,
  • Diagnosed with extra-pulmonary or drug resistant (MDR or XDR) TB based upon chart review
  • Current interfering untreated/unstable mental health condition (e.g., psychosis, bipolar dx)
  • Current use of non-study pharmacotherapy for smoking cessation,

This trial is currently available in South Africa.

  • University of Cape TownRondebosch, South AfricaContact: John Joska, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings.

The 2 groups in the trial

  • QUIT-ADTreatment being tested

    An six-session adapted cognitive-behavioral intervention for smoking cessation and treatment adherence. Intervention content will include psychoeducation related to cognitive-behavioral therapy, smoking, TB, and HIV; behavioral activation; distress tolerance; and relapse prevention.

  • Enhanced Treatment as Usual (ETAU)Existing treatment, for comparison

    After randomization, participants in the ETAU condition will receive one session of psychoeducation on the HIV- and TB-related health benefits of smoking cessation.

    Treatment: Enhanced Treatment as Usual

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Treatment Development for Smoking Cessation and Engagement in HIV/TB
Plain-language title
Tests a smoking quit program for people with HIV or TB in South AfricaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 September 2026